<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02677090</url>
  </required_header>
  <id_info>
    <org_study_id>15.10.NRC</org_study_id>
    <nct_id>NCT02677090</nct_id>
  </id_info>
  <brief_title>Fiber Tolerability in Children Aged 3-7 Year</brief_title>
  <acronym>Fiber - TIC</acronym>
  <official_title>Fiber Tolerability In Children Aged 3-7 Year</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nestlé</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nestlé</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Determination of the digestive tolerability of the PROMITOR® in children from 3 to 7 years
      old.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the trial is to determine, using a dose escalation design, the digestive
      tolerability of the PROMITOR®given at the doses of 6, then 9 and finally 12 g (corresponding
      to 4, 6, and 8 g of fibers respectively) twice a day with the meals of the morning and of the
      evening versus control (maltodextrin, no fiber) over one week of intake in children from 3 to
      7 years old.

      As it is an exploratory study there is no categorization between primary and secondary
      objectives.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of the digestive tolerability of the Investigational Product (abdominal pain) using analog visual scale</measure>
    <time_frame>7 days of intake</time_frame>
    <description>Using analog visual scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of the digestive tolerability of the Investigational Product (rumbling) using analog visual scale</measure>
    <time_frame>7 days of intake</time_frame>
    <description>Using analog visual scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of the digestive tolerability of the Investigational Product (bloating) using analog visual scale</measure>
    <time_frame>7 days of intake</time_frame>
    <description>Using analog visual scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of the digestive tolerability of the Investigational Product (flatulence) using analog visual scale</measure>
    <time_frame>7 days of intake</time_frame>
    <description>Using analog visual scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of the digestive tolerability of the Investigational Product (stools consistency &amp; frequency) using analog visual scale</measure>
    <time_frame>7 days of intake</time_frame>
    <description>Using analog visual scale</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Signs and Symptoms, Digestive</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 1 - Promitor®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Investigational product Dose 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 2 - Promitor®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Investigational product Dose 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 3 - Promitor®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Investigational product Dose 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (including Maltodextrin)</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dose 1 - Promitor®</intervention_name>
    <arm_group_label>Dose 1 - Promitor®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dose 2 - Promitor®</intervention_name>
    <arm_group_label>Dose 2 - Promitor®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dose 3 - Promitor®</intervention_name>
    <arm_group_label>Dose 3 - Promitor®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy children

          2. Aged between 3 and 7 years old

          3. Acceptance of the taste of the product

          4. Having breakfast on daily basis

          5. Consent and/or assent received according to regulation

          6. Informed consent of both parents/guardians (in respect with the French regulation)

          7. Parents/guardians affiliated to a health insurance (in respect with the French
             regulation)

        Exclusion Criteria:

          1. Specific food regimen

          2. Intolerability or food allergy

          3. Antibiotic or any medication impacting the gut transit during the 2 weeks before the
             study

          4. Chronic gastrointestinal disease

          5. Gastroenteritis in the 2 weeks preceding the study

          6. Constipation or diarrhea based on ROMEIII criteria (in average: more than 3 stools per
             day or less than 3 stools per week)

          7. Children and parents expected not to understand and perform the trial correctly (i.e.:
             troubles in learning and/or speaking)

          8. Child in a situation which, in the opinion of the principal investigator, could
             interfere with the optimal participation to the study or constitute a particular risk
             of non-compliance

          9. Having participated in another clinical trial for 1 month, or currently participating
             in a clinical trial

         10. Under legal protection or deprived from his rights following administrative or
             judicial decision (in respect with the French regulation)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>7 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Biofortis</name>
      <address>
        <city>Saint Herblain</city>
        <zip>44800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2016</study_first_submitted>
  <study_first_submitted_qc>February 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2016</study_first_posted>
  <last_update_submitted>March 9, 2016</last_update_submitted>
  <last_update_submitted_qc>March 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fiber tolerability</keyword>
  <keyword>Children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Signs and Symptoms</mesh_term>
    <mesh_term>Signs and Symptoms, Digestive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

